2/13/2018
AFP/Getty Images

The FDA granted approval to Novartis' Sandoz division for its 40 mg/mL Glatopa injection for the treatment of patients with multiple sclerosis. The agency previously approved selling a 20 mg/mL dosage of Glatopa.

Full Story:
Reuters

Related Summaries